1338732-65-2

Basic information

• Product Name: 5-hydroxymethyl-3-phenyl-4,5-dihydroisoxazole methanesulfonate
• Synonyms: 5-hydroxymethyl-3-phenyl-4,5-dihydroisoxazole methanesulfonate
• CAS NO: 1338732-65-2
• Molecular Weight: 255.295
• Mol File: 1338732-65-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-hydroxymethyl-3-phenyl-4,5-dihydroisoxazole methanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 5-hydroxymethyl-3-phenyl-4,5-dihydroisoxazole methanesulfonate(1338732-65-2)
• EPA Substance Registry System: 5-hydroxymethyl-3-phenyl-4,5-dihydroisoxazole methanesulfonate(1338732-65-2)

Safety Data

• Hazardous Substances Data: 1338732-65-2(Hazardous Substances Data)

Upstream product

• 68843-67-4 (E)-1-phenylbut-3-en-1-one oxime 
• 105551-42-6 (mesyloxyhydroxyiodo)benzene 
• 932-90-1 Benzaldoxime 
• 100-52-7 benzaldehyde 

Downstream Products

• 1338732-73-2 5-(N,N-dimethylaminomethyl)-3-phenyl-4,5-dihydroisoxazole 

Relevant articles and documents

Synthesis method of 3-aryl-4,5-dihydroisoxazole-5-yl-methyl sulfonate and analogs

The invention discloses a synthesis method of 3-aryl-4,5-dihydroisoxazole-5-ylmethyl p-toluenesulfonate and analogs, belonging to the technical field of organic chemistry. Iron (II) is used to catalyze Koser high iodine reagent (HIRS) to promote I-O bond

Synthesis and biochemical evaluation of δ2-isoxazoline derivatives as DNA methyltransferase 1 inhibitors

A series of Δ2-isoxazoline constrained analogues of procaine/procainamide (7a-k and 8a-k) were prepared and their inhibitory activity against DNA methyltransferase 1 (DNMT1) was tested. Among them, derivative 7b is far more potent in vitro (IC50 = 150 μM) than other non-nucleoside inhibitors and also exhibits a strong and dose-dependent antiproliferative effect against HCT116 human colon carcinoma cells. The binding mode of 7b with the enzyme was also investigated by means of a simple competition assay as well as of docking simulations conducted using the recently published crystallographic structure of human DNMT1. On the basis of the findings, we assessed that the mode of inhibition of 7b is consistent with a competition with the cofactor and propose it as a novel lead compound for the development of non-nucleoside DNMT inhibitors.